AcelRx Pharmaceuticals Inc. (ACRX) Jumps 21.72% on January 26

Equities Staff |

AcelRx Pharmaceuticals Inc. (ACRX) was among the biggest gainers on the Russell 2000 for Tuesday January 26 as the stock popped 21.72% to $3.81, representing a gain of $0.6798 per share. Some 1.36 million shares traded hands on 3,920 trades, compared with an average daily volume of 532,333 shares out of a total float of 44.45 million. The stock opened at $3.17 and traded with an intraday range of $3.84 to $3.02.

After today's gains, AcelRx Pharmaceuticals Inc. reached a market cap of $169.33 million. AcelRx Pharmaceuticals Inc. has had a trading range between $9.32 and $2.59 over the last year, and it had a 50-day SMA of $4.28 and a 200-day SMA of $4.04.

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of therapies for the treatment of acute pain.

AcelRx Pharmaceuticals Inc. is based out of Redwood City, CA and has some 32 employees. Its CEO is Howard Rosen.

For a complete fundamental analysis analysis of AcelRx Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for ACRX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…